胰高血糖素样肽-1联合复方左旋多巴治疗帕金森病合并糖尿病的效果

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (516 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of glucagon-like peptide-1 (GLP-1) combined with Compound Levodopa on Parkinson disease (PD) with diabetes mellitus (DM) patients. Methods A total of 158 PD with DM patients admitted to the First Affiliated Hospital of Hebei North University from January 2018 to June 2020 were selected as the research objects. They were divided into control group (79 cases) and research group (79 cases) according to the random number table method. The control group was given subcutaneous injection of insulin and oral Compound Levodopa Tablets, and the research group was given subcutaneous injection of GLP-1 and oral Compound Levodopa Tablets. The treatment time for both groups was six months. Before and after treatment, the changes of Montreal cognitive assessment scale (MoCA), unified Parkinson disease rating scale (UPDRS)Ⅱ (activity of daily living) and UPDRS Ⅲ (exercise ability) scores in UPDRS were compared. Results During the treatment, two patients in the research group dropped out, and 156 patients were eventually enrolled in the study. After treatment, MoCA score was higher than before treatment, UPDRS Ⅱ and Ⅲ scores were lower than before treatment, and the MoCA score of the research group was higher than that of the control group, and the UPDRS Ⅱ and Ⅲ scores were lower than that of the control group, with statistical significance (P ＜ 0.05). Conclusion GLP-1 combined with Compound Levodopa can not only improve the cognitive function of PD with DM patients, but also improve the quality of life and exercise ability of these patients.

Key words： Glucagon-like peptide-1 Compound Levodopa Parkinson disease Diabetes mellitus Effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FAN Lei LIU Xingliang LOU Zhan WANG Ying WANG Yuejuan

Cite this article:

FAN Lei LIU Xingliang LOU Zhan WANG Ying WANG Yuejuan. Effects of glucagon-like peptide-1 combined with Compound Levodopa on Parkinson disease with diabetes mellitus patients[J]. 中国医药导报, 2021, 18(29): 82-85.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I29/82

[1] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍学组.中国帕金森病治疗指南（第四版）[J].中华神经科杂志，2020，53（12）：973-986.
[2] Li G，Ma J，Cui S，et al. Parkinson’s disease in China：a forty-year growing track of bedside work [J]. Transl neurodegener，2019，8（1）：22.
[3] 胡静林，马俊，何雨茜，等.糖尿病与帕金森病的相关性研究进展[J].中华神经科杂志，2019，52（8）：665-669.
[4] 张克忠，王希希.国际运动障碍疾病协会帕金森病诊断新标准（2015）解读[J].重庆医科大学学报，2017，23（6）：687-689.
[5] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：292-344.
[6] Danne T，Nimri R，Battelino T，et al. International consensus on use of continuous glucose monitoring[J]. Diabetes Care，2017，40（12）：1631-1640.
[7] Nasreddine ZS，Phillips NA，Bédirian V，et al. The Montreal Cognitive Assessment，MoCA：a brief screening tool for mild cognitive impairment [J]. J Am Geriatr Soc，2005，53（4）：695-699.
[8] 温洪波，张振馨，牛富生，等.北京地区蒙特利尔认知量表的应用研究[J].中华内科杂志，2008，47（1）：36-39.
[9] 陈海波，王新德.统一帕金森病评定量表[J].中华老年医学杂志，1999，18（1）：61-62.
[10] 孔敏，巴茂文，梁辉，等.采用调查问卷评价帕金森病患者生活质量及影响因素研究[J].中华老年心脑血管病杂志，2014，16（9）：899-902.
[11] 杨柳，汪锡金.帕金森病与糖尿病的相关性研究进展[J].中国医药导报，2015，12（24）：40-43.
[12] 贺姣，薛兵，周玉霞，等.幽门螺杆菌感染对帕金森病合并糖尿病视网膜病变患者糖代谢和氧化应激及视网膜病变的影响[J].中华医院感染学杂志，2020，30（3）：409-413.
[13] 费露，丁正同.帕金森病与糖尿病相关性近十年的临床研究进展[J].中国临床神经科学，2018，26（3）：350-355.
[14] 朱冬梅，熊学智.左旋多巴联合卡巴拉汀治疗对帕金森病患者肌强直及多巴转运体的影响[J].医学临床研究，2018，35（5）：876-878，882.
[15] 岳秉宏，范磊，刘星亮，等.泰舒达对老年帕金森病合并糖尿病病人肢体感觉及自主神经症状的影响[J].中西医结合心脑血管病杂志，2017，15（9）：1128-1130.
[16] 冯斌，石正洪，栗静，等.帕金森病相关睡眠障碍的研究进展[J].神经疾病与精神卫生，2016，16（2）：221-224.
[17] 孙根，朱红灿，祝清勇.帕金森病合并认知功能障碍与脑白质纤维束改变的关系[J].中国神经免疫学和神经病学杂志，2019，26（1）：35-39.
[18] Santiago JA，Potashkin JA. Shared dysregulated pathways lead to Parkinson’s disease and diabetes [J]. Trends Mol Med，2013，19（3）：176-186.
[19] 何剑波，李会琪，翟洁敏，等.复方左旋多巴制剂与帕金森病患者同型半胱氨水平及认知损害的相关性分析[J].陕西医学杂志，2017，46（2）：250
[20] 韩玲，薛国芳，李东芳.胰高血糖素样肽-1受体激活在脑缺血中的神经保护作用[J].国际脑血管病杂志，2015， 23（5）：378-382.
[21] 蒋摇静，李俊峰，任丽伟，等.胰高血糖素样肽-1（GLP-1）对心血管疾病治疗的研究进展[J].复旦学报：医学版，2018，45（6）：123-129.
[22] 周永，陈蓝，戴杰，等.普拉克索联合左旋多巴治疗帕金森病的临床疗效及安全性[J].药物评价研究，2018，41（12）：136-139.
[23] 管子函，张炳才，郑乐群.胰高血糖素样肽-1类似物联合二甲双胍对肥胖2型糖尿病患者血糖及胰岛素抵抗的影响[J].中华内分泌外科杂志，2019，13（2）：144-149.
[24] 阚全娥，杨慧慧，于璐，等.肥胖2型糖尿病患者胰高血糖素样肽-1干预前后血清Wnt5a和Sfrp5水平变化及意义[J].中华实用诊断与治疗杂志，2019，33（12）：1222-1225.
[25] 唐松涛.胰高血糖素样肽-1对晚期糖基化终末产物诱导血管内皮细胞肌球蛋白轻链磷酸化的影响及机制研究[D].合肥：安徽医科大学，2016：1-10.
[26] Briyal S，Shah S，Gulati A. Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia[J]. Neuroscience，2014，281：269-281.